Atomo Diagnostics (AT1) Q3 2026 earnings summary

Executive summary

• Achieved a transformative Q3 with strong momentum in HIV tests and Pascal cassettes, expanding into new products, partners, and global markets.

• Expanded product pipeline with advanced HIV, syphilis, and liver function tests, securing key regulatory milestones and an exclusive global license for a novel liver test.

• CLIA waiver for Lumos' FebriDx test in the U.S. validates Pascal platform and opens significant U.S. market pathways.

• Completed a $3 million capital raise, maintaining a debt-free balance sheet and supporting operational expansion.

• Expanded commercial footprint with sales channels in Australia, US, Europe, Asia, and Africa.

Financial highlights

• Q3 FY26 revenue reached $814,000, with year-to-date revenue of approximately $3 million, up 4% year-over-year.

• Cash on hand at quarter-end was AUD 2.6 million, with customer receipts exceeding AUD 1.6 million and nearly AUD 200,000 in government grants.

• Operating expenses for the quarter were $1.8 million, with cash outflows totaling AUD 2.6 million focused on delivery and new product development.

• Balance sheet strengthened by a capital raise at quarter-end, not yet reflected in reported numbers.

• EBITDA trending toward breakeven as revenue channels grow and product offerings expand.

Outlook and guidance

• Anticipates transformational growth in Pascal revenues following US FDA CLIA waiver for FebriDx, unlocking significant US market potential.

• Expects significant revenue growth in Q4 and a strong finish to FY 2026, with momentum into FY 2027.

• Plans to leverage existing HIV infrastructure for rapid, capital-efficient market entry of new syphilis and liver function tests.

• EBITDA losses are narrowing, with a trajectory toward break-even as revenue expands.

• No specific net profit timeline, but confident in the path to profitability.